JP7098648B2 - 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 - Google Patents

臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 Download PDF

Info

Publication number
JP7098648B2
JP7098648B2 JP2019548664A JP2019548664A JP7098648B2 JP 7098648 B2 JP7098648 B2 JP 7098648B2 JP 2019548664 A JP2019548664 A JP 2019548664A JP 2019548664 A JP2019548664 A JP 2019548664A JP 7098648 B2 JP7098648 B2 JP 7098648B2
Authority
JP
Japan
Prior art keywords
cells
cell
hank003
irradiated
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511131A5 (enExample
JP2020511131A (ja
Inventor
ハンス クリンゲマン
ローラン ボワセル
パトリック スン－シオン
Original Assignee
イミュニティーバイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュニティーバイオ インコーポレイテッド filed Critical イミュニティーバイオ インコーポレイテッド
Publication of JP2020511131A publication Critical patent/JP2020511131A/ja
Publication of JP2020511131A5 publication Critical patent/JP2020511131A5/ja
Priority to JP2022104262A priority Critical patent/JP7398518B2/ja
Application granted granted Critical
Publication of JP7098648B2 publication Critical patent/JP7098648B2/ja
Priority to JP2023204311A priority patent/JP7608580B2/ja
Priority to JP2024221238A priority patent/JP2025038128A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019548664A 2017-03-08 2018-03-07 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 Active JP7098648B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022104262A JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2023204311A JP7608580B2 (ja) 2017-03-08 2023-12-04 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2024221238A JP2025038128A (ja) 2017-03-08 2024-12-18 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468890P 2017-03-08 2017-03-08
US62/468,890 2017-03-08
PCT/US2018/021332 WO2018165291A1 (en) 2017-03-08 2018-03-07 MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022104262A Division JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞

Publications (3)

Publication Number Publication Date
JP2020511131A JP2020511131A (ja) 2020-04-16
JP2020511131A5 JP2020511131A5 (enExample) 2021-04-08
JP7098648B2 true JP7098648B2 (ja) 2022-07-11

Family

ID=63446373

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019548664A Active JP7098648B2 (ja) 2017-03-08 2018-03-07 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2022104262A Active JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2023204311A Active JP7608580B2 (ja) 2017-03-08 2023-12-04 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2024221238A Pending JP2025038128A (ja) 2017-03-08 2024-12-18 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022104262A Active JP7398518B2 (ja) 2017-03-08 2022-06-29 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2023204311A Active JP7608580B2 (ja) 2017-03-08 2023-12-04 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP2024221238A Pending JP2025038128A (ja) 2017-03-08 2024-12-18 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞

Country Status (9)

Country Link
US (4) US10801013B2 (enExample)
EP (1) EP3592845A4 (enExample)
JP (4) JP7098648B2 (enExample)
KR (4) KR102769529B1 (enExample)
CN (2) CN110418839B (enExample)
AU (2) AU2018231193B2 (enExample)
CA (1) CA3053252C (enExample)
IL (2) IL316209A (enExample)
WO (1) WO2018165291A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic
CN119752802A (zh) 2018-08-01 2025-04-04 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
KR102665280B1 (ko) * 2018-10-31 2024-05-10 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거
EP3886873A1 (en) * 2018-11-26 2021-10-06 ImmunityBio, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
WO2020205100A1 (en) * 2019-03-15 2020-10-08 Nantcell, Inc. Recombinant eril-15 nk cells
KR20220041850A (ko) * 2019-07-26 2022-04-01 난트퀘스트, 인크. 종양 용해를 위한 효과적인 치료 산물로서의 항체 사전 로드된 cd16+nk-92 세포
AU2020387167B2 (en) * 2019-11-20 2024-10-24 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
WO2021116913A1 (en) * 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
AU2021305084A1 (en) 2020-07-07 2023-02-02 Cancure, Llc MIC antibodies and binding agents and methods of using the same
CA3199435A1 (en) * 2020-10-26 2022-05-05 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
WO2024003723A1 (en) * 2022-06-28 2024-01-04 Cellply S.R.L. Method for the characterization of products for cell therapy
US20250298030A1 (en) * 2024-03-20 2025-09-25 Immunitybio, Inc. Compositions and Methods for NK-92 Cells Expressing Native CD16

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292156A1 (en) 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines
WO2016160602A2 (en) 2015-03-27 2016-10-06 Nantkwest, Inc. Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
WO2016201304A1 (en) 2015-06-10 2016-12-15 Nantkwest, Inc. Modified nk-92 cells for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227584A1 (en) * 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
CA2289915A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
EP1007630B1 (en) 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292156A1 (en) 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines
WO2016160602A2 (en) 2015-03-27 2016-10-06 Nantkwest, Inc. Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
WO2016201304A1 (en) 2015-06-10 2016-12-15 Nantkwest, Inc. Modified nk-92 cells for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Guitta maki et.al.，Factors regulating the cytotoxic activity of the human natural killer cell line; NK-92，Journal of hematotherapy & stem cell research，2001年，vol.10, no.3，pp369-383

Also Published As

Publication number Publication date
KR20240010558A (ko) 2024-01-23
KR102769529B1 (ko) 2025-02-19
JP2020511131A (ja) 2020-04-16
US12492377B2 (en) 2025-12-09
AU2021236511B2 (en) 2021-12-16
AU2021236511A1 (en) 2021-10-28
US20200347351A1 (en) 2020-11-05
KR20230074281A (ko) 2023-05-26
KR102533061B1 (ko) 2023-05-15
IL268617B1 (en) 2024-11-01
JP7398518B2 (ja) 2023-12-14
CN116440293A (zh) 2023-07-18
KR20250026391A (ko) 2025-02-25
JP2022130596A (ja) 2022-09-06
JP7608580B2 (ja) 2025-01-06
CN110418839B (zh) 2023-06-09
US20190300854A1 (en) 2019-10-03
CA3053252C (en) 2023-02-21
IL268617A (en) 2019-10-31
KR102626748B1 (ko) 2024-01-17
AU2018231193B2 (en) 2021-07-22
US20240010979A1 (en) 2024-01-11
JP2024023513A (ja) 2024-02-21
AU2018231193A1 (en) 2019-08-08
US10774310B2 (en) 2020-09-15
IL268617B2 (en) 2025-03-01
CN110418839A (zh) 2019-11-05
EP3592845A4 (en) 2020-12-30
US10801013B2 (en) 2020-10-13
US20180258397A1 (en) 2018-09-13
JP2025038128A (ja) 2025-03-18
WO2018165291A1 (en) 2018-09-13
US11753625B2 (en) 2023-09-12
EP3592845A1 (en) 2020-01-15
CA3053252A1 (en) 2018-09-13
KR20190118204A (ko) 2019-10-17
IL316209A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
JP7098648B2 (ja) 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
JP7275178B2 (ja) がんを処置するための改変ｎｋ－９２細胞
JP7092404B2 (ja) Ｐｄ－ｌ１キメラ抗原受容体を発現するｎｋ細胞によるｐｄ－ｌ１陽性悪性腫瘍の排除
JP2017534280A (ja) 腫瘍を標的にするがｔ細胞を標的にしないサバイビン特異的ｔ細胞受容体
CN113164521A (zh) 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
US20240181056A1 (en) Chimeric antigen receptor (car)-t cells
CN116867519A (zh) 治疗t细胞癌症的方法和材料
US20240207312A1 (en) Chimeric antigen receptor (car)-t cells
US20240207313A1 (en) Chimeric antigen receptor (car)-t cells
HK40011833A (en) Modified nk-92 hank003 cells for the clinic
HK1251016A1 (en) Modified nk-92 cells for treating cancer
HK1251016B (en) Modified nk-92 cells for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220629

R150 Certificate of patent or registration of utility model

Ref document number: 7098648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250